MassMutual Private Wealth & Trust FSB Sells 3,783 Shares of AbbVie Inc. $ABBV

MassMutual Private Wealth & Trust FSB trimmed its position in AbbVie Inc. (NYSE:ABBV) by 2.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 177,556 shares of the company’s stock after selling 3,783 shares during the quarter. AbbVie comprises approximately 1.0% of MassMutual Private Wealth & Trust FSB’s holdings, making the stock its 21st largest position. MassMutual Private Wealth & Trust FSB’s holdings in AbbVie were worth $41,111,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ABBV. Conning Inc. boosted its stake in AbbVie by 7.1% during the 2nd quarter. Conning Inc. now owns 191,023 shares of the company’s stock valued at $35,458,000 after purchasing an additional 12,690 shares during the period. Diversified Trust Co lifted its holdings in shares of AbbVie by 23.6% during the third quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after buying an additional 10,891 shares during the last quarter. Dohj LLC boosted its position in shares of AbbVie by 41.8% in the second quarter. Dohj LLC now owns 4,529 shares of the company’s stock valued at $802,000 after acquiring an additional 1,335 shares during the period. Permanent Capital Management LP bought a new stake in shares of AbbVie in the third quarter valued at approximately $720,000. Finally, Railway Pension Investments Ltd grew its stake in shares of AbbVie by 33.0% in the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after acquiring an additional 211,800 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Up 1.7%

NYSE:ABBV opened at $223.88 on Wednesday. The firm has a market capitalization of $395.69 billion, a PE ratio of 169.61, a price-to-earnings-growth ratio of 0.92 and a beta of 0.36. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The firm has a 50-day moving average price of $226.46 and a 200 day moving average price of $214.67.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the previous year, the business earned $3.00 earnings per share. The company’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is currently 496.97%.

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of research reports. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and increased their price target for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. JPMorgan Chase & Co. increased their target price on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. BMO Capital Markets lifted their target price on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a research report on Friday, September 12th. Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 10th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $246.89.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.